Belantamab mafodotin
- Generic Name
- Belantamab mafodotin
- Brand Names
- BLENREP
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050232-20-5
- Unique Ingredient Identifier
- DB1041CXDG
- Background
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufacturer began the process for withdrawal of the US marketing authorization in November 2022. In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.
- Indication
Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma
Blenrep (belantamab mafodotin) combination accepted for priority review in China
FDA Accepts GSK's Biologics License Application of Blenrep for Relapsed or Refractory
Year in Review: Multiple Myeloma
GSK eyes up combo approval for previously withdrawn myeloma drug
Related Clinical Trials:
GSK's Blenrep combinations accepted for review by US FDA
FDA Accepts Blenrep Combination For Review In Treatment Of Relapsed/Refractory
Blenrep combinations accepted for review by the US FDA for the treatment of relapsed
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.